As the field of regenerative medicine continues to advance, the incorporation of AI is playing a transformative role in the ...

Novo Nordisk and AI-driven protein design company Gensaic are to develop tissue-targeted therapies for cardiometabolic ...

The EC has authorised the marketing of Bavarian Nordic's Vimkunya chikungunya vaccine for individuals as young as 12 years ...

Regenerative medicine, a rapidly advancing field, can be generally defined as a therapeutic methodology for the repair, ...

AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire rights to a long-acting amylin ...

BridgeBio Oncology has entered into a merger agreement with Helix Acquisition Corp II to form a combined entity.

Magnet Biomedicine has entered a partnership and licence agreement with Eli Lilly for molecular glue therapeutics.

Avtozma is the 12th biosimilar from Celltrion to receive approval from the EC. Credit: © CELLTRION INC. All Rights Reserved.

As Rare Disease Day is commemorated on 28 February, experts discuss the barriers to gene therapy access for some rare ...

The company's IPO follows a $182m Series C funding round last year.

Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...

Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft ...